Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone Marrow Clinical Trials**

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-098**

**Phase I**

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

**STUDY 2015-115**

**Phase II**

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY 2016-109**

**Phase II**

A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies (Protocol Number 15-MMUD).
STUDY 2014-103
Phase I/II
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY BMTCTN1302
Phase II
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma.

STUDY BMTCTN1102
Phase III
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.

STUDY NEW 2016-209
Phase II
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

STUDY 2011-203
Phase I/I
Phase I/I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.

STUDY 2016-032
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

STUDY NEW 2016-194
Phase III
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

STUDY 2016-049
Phase I/I
A Phase 1 Non-randomized/2 Randomized Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies.

STUDY 2011-086
NA
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

RETURN TO TOP

Breast Clinical Trials
For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT
STUDY S1207
Phase III
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer - e3 Breast Cancer Study - evaluating
Everolimus with Endocrine Therapy.

**STUDY NRG-BR003**
Phase III
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

**STUDY A011202**
Phase III
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

**ADJUVANT HORMONAL**
**STUDY 2016-016**
Phase I/II
A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR)

**NEoadjuvant**
**STUDY 2015-137**
Phase I
A Phase 1b, Open-Label, Two-Arm Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab in Patients with HER-Positive Breast Cancer

**STUDY RTOG1304**
Phase III
NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

**STUDY EA1131**
Phase III
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neo-adjuvant Chemotherapy

**STUDY 2016-002**
Phase II
A Randomized Multi-center Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination with Folate Receptor Alpha Peptides with GM-CSF in Patients with Triple Negative Breast Cancer

**ADVANCED (Stage IV) CHEMOTHERAPY**
**STUDY 2013-120**
Phase I
A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents

**STUDY 2016-030**
Phase I
Phase Ib Study to Assess the Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)+

**STUDY 2016-050**
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.
<table>
<thead>
<tr>
<th>STUDY</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2013-119</td>
<td>Phase I</td>
<td>A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2015-137</td>
<td>Phase I</td>
<td>A Phase 1b, Open-Label, Two-Arm Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab in Patients with HER2-Positive Breast Cancer</td>
</tr>
<tr>
<td>HORMONAL</td>
<td>STUDY 2015-046</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2013-119</td>
<td>Phase I</td>
<td>A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-034</td>
<td>Phase I</td>
<td>A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2015-137</td>
<td>Phase I</td>
<td>A Phase 1b, Open-Label, Two-Arm Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab in Patients with HER2-Positive Breast Cancer</td>
</tr>
<tr>
<td>OTHERS</td>
<td>STUDY 2016-025</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2016-123</td>
<td>Phase III</td>
<td>A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)</td>
</tr>
<tr>
<td>STUDY 2016-189</td>
<td>Phase I</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-157</td>
<td>Phase I/II</td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY 2016-116</td>
<td>Phase II</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
STUDY 2015-086  
Phase I  
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

STUDY 2014-100  
Phase II  
Cryoablation of Low Risk Breast Cancers less than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)

STUDY EAY131  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

Gastrointestinal Clinical Trials

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ESOPHAGUS

STUDY 2016-001  
Phase I  
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

STUDY 2016-050  
Phase I  
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2016-025  
Phase I/II  
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

GASTRIC AND GASTROESOPHAGEAL JUNCTION

Metastatic

STUDY 2013-162  
Phase I  
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

STUDY NEW 2016-210  
Phase I/II  
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2015-047  
Phase I  
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

STUDY 2015-103
Phase I
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

STUDY 2016-001
Phase I
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-025
Phase I/II
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL- 12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

STUDY 2015-161
Phase I/II
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

PANCREAS
Adenocarcinoma
Borderline Resectable
STUDY NEW A021501
Phase III
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Metastatic
STUDY S1513
Phase II
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

STUDY 2013-133
Phase I/II
A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

STUDY 2016-011
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab- Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
### Neuroendocrine

**STUDY EA2142**  
*Phase II*  
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

**STUDY NEW EA2161**  
*Phase II*  
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)

**STUDY 2016-025**  
*Phase I/II*  
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

**STUDY 2016-116**  
*Phase II*  
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

**STUDY 2013-133**  
*Phase I/II*  
A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

**STUDY 2016-001**  
*Phase I*  
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

### HCC Metastatic

**STUDY 2016-025**  
*Phase I/II*  
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

**STUDY 2015-086**  
*Phase I*  
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

**STUDY 2016-064**  
*Phase III*  
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

**STUDY 2016-039**  
*Phase I/II*  
A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma

**STUDY 2016-079**  
*Phase I*  
An Open-Label Multicenter Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
BILIARY/GALL BLADDER

Metastatic
STUDY 2016-186
Phase II
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

STUDY 2014-081
Phase II
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy

STUDY 2016-041
Phase II
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer

Metastatic (Includes Rectal)
1st Line
STUDY 2015-086
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

2nd Line
STUDY 2015-086
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2015-131
Phase II
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2015-110
Phase I/II
A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varilimumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
STUDY 2016-063
TITLE
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

STUDY 2016-092
Phase I
An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors

STUDY E7208
Phase II
A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wildtype Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

STUDY 2016-001
Phase I
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-025
Phase I/II
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

RECTUM
STUDY 2016-025
Phase I/II
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

STUDY 2016-063
TITLE
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

ANAL
Localized
STUDY EA2133
Phase II
InterAACT: An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease

Metastatic
STUDY EA2133
Phase II
InterAACT: An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease

STUDY 2015-108
Phase II
Phase 2 Study of ADXS11-001 in Subjects with Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Genitourinary Clinical Trials
For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

RENAL
STUDY S1500
Phase II
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2016-078
Phase I/II
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination with Axitnib in Patients with Advanced Renal Cell Carcinoma

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2015-168
Phase III
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

STUDY 2016-201
Phase III
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

STUDY NEW 2017-013
Phase I
A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2a Inhibitor in Patients with Advanced Clear Cell Renal Cell Carcinoma
STUDY 2016-126  
Phase II  
Phase II Study of Atezolizumab + Bevacizumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

STUDY 2016-050  
Phase I  
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2016-157  
Phase I  
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2016-055  
Phase I  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2009-139  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2014-010  
Phase I  
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4

STUDY 2015-156  
Phase I  
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

STUDY 2013-162  
Phase I  
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

STUDY 2015-109  
Phase I  
A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics And Pharmacodynamics of Axitinib (AG-013736) in Combination With Crizotinib (PF-02341066) in Patients With Advanced Solid Tumors

PROSTATE  
STUDY 2013-108  
NA  
Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

STUDY 2014-075  
Phase I  
Targeting the Prostatic Tumor Microenvironment with PLX3397, a Tumorassociated Macrophage Inhibitor, in Men with Unfavorable Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy

STUDY 2016-157  
Phase I  
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2015-059  
Phase II
A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone

**STUDY 2016-153**
*Phase I*
A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

**STUDY 2015-029**
*Phase II*
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy

**STUDY 2016-028**
*Phase I*
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients with Metastatic Castration-Resistant Prostate Cancer

**STUDY 2015-033**
*Phase III*
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy

**STUDY 2015-086**
*Phase I*
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

**STUDY 2015-057**
*Phase I*
A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014

**STUDY 2015-096**
*Phase I/II*
A Phase 1/2 Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral EPI-506 in Patients with Metastatic Castration-resistant Prostate Cancer

**STUDY 2015-050**
*Phase II*
A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

**BLADDER**

**STUDY 2016-055**
*Phase I*
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2013-162**
*Phase I*
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

**STUDY 2016-050**
*Phase I*
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.
<table>
<thead>
<tr>
<th>STUDY 2015-084</th>
<th>Phase III</th>
<th>A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti- PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With, High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-003</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>STUDY S1314</td>
<td>Phase II</td>
<td>A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer</td>
</tr>
<tr>
<td>STUDY 2015-101</td>
<td>Phase I/II</td>
<td>A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in patients with BCG-naïve Non-Muscle Invasive Bladder Cancer</td>
</tr>
<tr>
<td>STUDY 2016-175</td>
<td>Phase II</td>
<td>A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-052</td>
<td>Phase III</td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy</td>
</tr>
<tr>
<td>STUDY 2014-010</td>
<td>Phase I</td>
<td>A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4</td>
</tr>
<tr>
<td>STUDY 2015-072</td>
<td>Phase II</td>
<td>A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy</td>
</tr>
<tr>
<td>STUDY 2013-120</td>
<td>Phase I</td>
<td>A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents</td>
</tr>
<tr>
<td>OTHER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY EAY131</td>
<td>Phase II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>STUDY 2016-189</td>
<td>Phase I</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-156</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody</td>
</tr>
</tbody>
</table>
(BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

**RETURN TO TOP**

## Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at [313-576-9790](tel:313-576-9790). To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at [800-527-6266](tel:800-527-6266), email [newpt@karmanos.org](mailto:newpt@karmanos.org) or fill out this [online referral form](#).

**CERVIX**

**STUDY NEW GOG-3009**

**Phase III**

Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

**OVARY**

**STUDY 2015-110**

**Phase I/II**

A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

**STUDY 2015-157**

**Phase I/II**

Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer

**STUDY 2016-121**

**Phase II**

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

**STUDY 2016-025**

**Phase I/II**

A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

**STUDY NRG-GY004**

**Phase III**

Phase III Study Comparing Single Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer

**STUDY 2016-037**

**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY NEW 2016-204**

**Phase II**

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

**STUDY NEW NRG-GY003**

**Phase II**

Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary
<table>
<thead>
<tr>
<th>STUDY 2016-128</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIEL4 (Assessment of Rucaparib In Ovarian CancEr Trial): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY 2013-120</th>
<th>Phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY 2015-066</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations</td>
<td></td>
</tr>
</tbody>
</table>

<p>| UTERUS |</p>
<table>
<thead>
<tr>
<th>STUDY GOG-0238</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY NRG-GY008</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase II Evaluation of Copanlisib (BAY 80-6946) (Ind #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY 2015-086</th>
<th>Phase I</th>
</tr>
</thead>
<tbody>
<tr>
<td>A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies</td>
<td></td>
</tr>
</tbody>
</table>

<p>| VULVAR |</p>
<table>
<thead>
<tr>
<th>STUDY GOG-0279</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva</td>
<td></td>
</tr>
</tbody>
</table>

<p>| OTHER |</p>
<table>
<thead>
<tr>
<th>STUDY 2016-121</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase 2, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY NEW 2016-204</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STUDY EAY131</th>
<th>Phase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
<td></td>
</tr>
</tbody>
</table>
Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGES I/II/III
STUDY 2016-093
Phase I/II
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY 2016-174
Phase I/II
Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY NEW 2017-027
Phase II
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients with Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma who Progressed on Standard Treatment

STUDY NEW 2017-003
Phase III
A Randomized Phase III Study of Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy versus Chemoradiation Alone in Subjects with Locally Advanced Head and Neck Squamous Cell Carcinoma

STUDY 2016-165
TITLE
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

STAGES I - IV
STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

ANY STAGE
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2016-001
Phase I
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)
STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

STUDY 2016-149
Phase I/II
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

OTHER
STUDY 2015-110
Phase I/II
A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2016-025
Phase I/II
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

STUDY 2015-086
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, FullyHuman Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

Hematology Clinical Trials
For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

MULTIPLE MYELOMA
STUDY 2015-129
Phase I/II
A Phase 1/2 Open label Study of SL-401 in combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

STUDY 2015-008
<table>
<thead>
<tr>
<th><strong>Phase I/II</strong></th>
<th><strong>Investigator-initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma</strong></th>
</tr>
</thead>
</table>
| **STUDY NEW 2016-146** | **Phase I**  
**Phase 1 Study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma** |
| **STUDY NEW 2017-005** | **Phase I/II**  
**A Phase 1/2, Open-Label Safety, Pharmacokinetic, and Efficacy Study of TAS4464 in Patients with Multiple Myeloma or Lymphoma** |
| **STUDY 2012-122** | **Phase I/II**  
**Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma** |
| **STUDY 2016-119** | **Phase I**  
**An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients with Relapsed/Refractory Multiple Myeloma** |
| **STUDY E1A11** | **Phase III**  
**Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)** |
| **STUDY 2014-054** | **Phase I/II**  
**A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies** |
| **STUDY 2016-086** | **Phase I**  
**A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma** |
| **STUDY 2010-106** | **Phase III**  
**A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age** |
| **STUDY 2016-179** | **Phase II**  
**Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation** |
| **STUDY 2015-022** | **Phase I**  
**A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (ANTIPD- L1 ANTIBODY) Alone or in Combination with an Immunomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed and Post- Autologous Stem Cell Transplantation)** |
| **STUDY E3A06** | **Phase III**  
**Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple** |
Myeloma

**STUDY 2015-036**
**Phase II**
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

**AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE**
**STUDY 2012-086**
**Phase III**
A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

**LEUKEMIA**

**Acute Lymphoblastic Leukemia (ALL)**
**STUDY E1910**
**Phase III**
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABLnegative B lineage Acute Lymphoblastic Leukemia in Adults

**STUDY S1318**
**Phase II**
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL

**STUDY 2015-054**
**Phase I**
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 64052781, a Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects with Relapsed or Refractory B-cell Malignancies

**Acute Myeloid Leukemia (AML)**
**STUDY 2014-031**
**Phase III**
A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy In Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-Line Treatment With or Without Hematopoietic Stem Cell Transplant(HSCT) Consolidation

**STUDY 2016-035**
**Phase I**
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

**STUDY 2016-140**
**Phase III**
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

**STUDY 2016-103**
**Phase I**
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

**Chronic Lymphocytic Leukemia (CLL)**
**STUDY 2013-140**
<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td>A Phase IB, Open-Label Study Evaluating The Safety and Pharmacokinetics of Venetoclax (GDC-0199 [ABT-199]) in Combination with Bendamustine/Rituximab (BR) or Bendamustine-Obinutuzumab (BG) in Patients with Relapsed Refractory or Untreated Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td>STUDY NEW 2015-054</td>
<td>Phase I&lt;br&gt;A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ- 64052781, a Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects with Relapsed or Refractory B-cell Malignancies</td>
</tr>
<tr>
<td>Chronic Myeloid Leukemia (CML)</td>
<td>STUDY 2015-128&lt;br&gt;Phase II&lt;br&gt;A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses</td>
</tr>
<tr>
<td>LYMPHOMA</td>
<td>Hodgkin's&lt;br&gt;STUDY NEW 2016-033&lt;br&gt;Phase II&lt;br&gt;A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma</td>
</tr>
<tr>
<td>STUDY 2015-126</td>
<td>Phase I/II&lt;br&gt;A Study Evaluating Brentuximab Vedotin in Combination with the PD-1 Inhibitor Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma after Failure of Frontline Therapy</td>
</tr>
<tr>
<td>STUDY 016-058</td>
<td>Phase III&lt;br&gt;A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Non-Hodgkin's</td>
<td>Aggressive (Mantle Cell, Large B-Cell Lymphoma)&lt;br&gt;STUDY 2015-054&lt;br&gt;Phase I&lt;br&gt;A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64052781, a Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects with Relapsed or Refractory B-cell Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-057</td>
<td>Phase II&lt;br&gt;Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>STUDY 2014-133</td>
<td>Phase III&lt;br&gt;Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma</td>
</tr>
<tr>
<td>STUDY 2013-178</td>
<td>Phase I/II&lt;br&gt;A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>STUDY 2017-007</td>
<td>Phase I</td>
</tr>
<tr>
<td>Study ID</td>
<td>Phase</td>
</tr>
<tr>
<td>------------------</td>
<td>-------</td>
</tr>
<tr>
<td>STUDY 2015-125</td>
<td>II</td>
</tr>
<tr>
<td>STUDY 2013-047</td>
<td>I</td>
</tr>
<tr>
<td>STUDY NEW 2016-147</td>
<td>II</td>
</tr>
<tr>
<td>STUDY 2015-150</td>
<td>I/II</td>
</tr>
<tr>
<td>STUDY 2009-139</td>
<td>I</td>
</tr>
<tr>
<td>STUDY 2016-139</td>
<td>I</td>
</tr>
<tr>
<td>STUDY NEW 2016-125</td>
<td>I/II</td>
</tr>
<tr>
<td>STUDY NEW 2016-210</td>
<td>I/II</td>
</tr>
<tr>
<td>STUDY 2017-008</td>
<td>I</td>
</tr>
<tr>
<td><strong>MYELODYSPLASTIC SYNDROME (MDS)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phase I</td>
</tr>
<tr>
<td><strong>STUDY 2016-035</strong></td>
<td>Phase I</td>
</tr>
</tbody>
</table>
Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

**STUDY 2016-054**  
**Phase III**  
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions (The "MEDALIST" Trial)

**OTHER**  
**STUDY 2016-024**  
**Phase I**  
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

**STUDY 2013-113**  
**Phase II**  
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI 32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

**STUDY 2016-148**  
**Phase I/II**  
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies

**STUDY EAY131**  
**Phase II**  
Molecular Analysis for Therapy Choice (MATCH)

**Immunotherapy Clinical Trials**

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

**Melanoma/Skin Clinical Trials**

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**ADJUVANT**  
**STUDY S1404**  
**Phase III**  
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

**ADVANCED**  
**STUDY 2015-034**  
**Phase I/II**  
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors
STUDY NEW 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2016-015
Phase II
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY EA6134
Phase III
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

STUDY 2015-004
Phase II
A Multi-Center Phase 2 Open Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY S1320
Phase II
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

OTHER
STUDY 2015-086
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

STUDY 2015-117
Phase III
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced
Solid Tumors

**STUDY 2016-149**
**Phase I/II**
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

**STUDY 2016-055**
**Phase I**
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY EAY131**
**Phase II**
Molecular Analysis for Therapy Choice (MATCH)

**RETURN TO TOP**

Neuro-Oncology Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

**RETURN TO TOP**

Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

**ALL SOLID TUMORS**

**STUDY 2012-069**
**Phase I**
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, And Pharmacokinetic Study Of TAS-114 In Combination With Capecitabine In Patients With Advanced Solid Tumors TAS-114

**STUDY 2011-166**
**Phase I**
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

**STUDY 2015-005**
**Phase I**
A Phase 1A Dose-Escalation Study of OBP-801 in Patients with Advanced Solid Tumors.

**STUDY 2016-050**
**Phase I**
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

**STUDY NEW 2016-170**
<table>
<thead>
<tr>
<th>Study Id</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-189</td>
<td>Phase I</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2016-210</td>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>2016-135</td>
<td>Phase I</td>
<td>A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2015-156</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors</td>
</tr>
<tr>
<td>2015-011</td>
<td>Phase I</td>
<td>A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate, Sunitinib Malate, and Regorafenib</td>
</tr>
<tr>
<td>2015-034</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors</td>
</tr>
<tr>
<td>2014-116</td>
<td>Pilot</td>
<td>Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders</td>
</tr>
<tr>
<td>2015-149</td>
<td>Phase I</td>
<td>A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects with Advanced or Recurrent Solid Tumors</td>
</tr>
<tr>
<td>2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2015-109</td>
<td>Phase I</td>
<td>A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics And Pharmacodynamics of Axitinib (AG-013736) in Combination With Crizotinib (PF-02341066) in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>2009-139</td>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td>Study Number</td>
<td>Phase</td>
<td>Title</td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>STUDY 2013-119</td>
<td>Phase I</td>
<td>A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2011-082</td>
<td>Phase I</td>
<td>An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors (NCI# 8808, UPCI# 10-115)</td>
</tr>
<tr>
<td>STUDY 2015-086</td>
<td>Phase I</td>
<td>A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-075</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2011-002</td>
<td>Phase I</td>
<td>Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction</td>
</tr>
<tr>
<td>TUMOR SPECIFIC</td>
<td>STUDY 2013-162</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2015-110</td>
<td>Phase I/II</td>
<td>A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2015-157</td>
<td>Phase I/II</td>
<td>Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer</td>
</tr>
<tr>
<td>STUDY 2015-034</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors</td>
</tr>
<tr>
<td>STUDY NEW 2016-210</td>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>Study</td>
<td>Phase</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td>STUDY 2015-109</td>
<td>Phase I</td>
<td>A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics And Pharmacodynamics of Axitinib (AG-013736) in Combination With Crizotinib (PF-02341066) in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-096</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral EPI-506 in Patients with Metastatic Castration-resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2013-120</td>
<td>Phase I</td>
<td>A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents</td>
</tr>
<tr>
<td>STUDY 2013-047</td>
<td>Phase I</td>
<td>A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas</td>
</tr>
<tr>
<td>STUDY 2015-046</td>
<td>Phase I</td>
<td>A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2015-047</td>
<td>Phase I</td>
<td>A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2013-119</td>
<td>Phase I</td>
<td>A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2015-137</td>
<td>Phase I</td>
<td>A Phase 1b, Open-Label, Two-Arm Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab in Patients with HER2-Positive Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2016-001</td>
<td>Phase I</td>
<td>A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects with Advanced Solid Tumors and in Subjects with Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)</td>
</tr>
<tr>
<td>STUDY 2016-079</td>
<td>Phase I</td>
<td>An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma</td>
</tr>
<tr>
<td>STUDY 2016-016</td>
<td>Phase I/II</td>
<td>A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR)</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
GENOMIC TESTING SPECIFIC
STUDY 2015-047
Phase I
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors.

STUDY 2015-137
Phase I
A Phase 1b, Open-Label, Two-Arm Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab in Patients with HER2-Positive Breast Cancer

RETURN TO TOP

Sarcoma Clinical Trials
There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Thoracic Clinical Trials
For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT
STUDY 2015-080
Phase III
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (ANTI-PD-L1 ANTIBODY) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1-Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

STAGE I/II
STUDY E4512
Phase III
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer
STUDY NEW A081105
Phase III
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

STAGE III A/B
STUDY 2015-103
Phase I
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

STUDY S1206
Phase I/II
A Dose Finding Study Followed by Phase II Randomized Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC). (NCI STUDY NUMBER 8811)

STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STAGE IV
ALK
STUDY 2014-071
Phase I/II
Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2015-131
Phase II
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

EGFR
STUDY 2015-133
Phase II
A Phase II, Multicenter, Three-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR wild-type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC) who have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

Other Genetic Marker
STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STUDY 2014-002
Phase II
A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.

STUDY 2015-103
Phase I
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

STUDY 2015-026
Phase II
A Phase II, Open-label Study of Ponatinib, a Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small-Cell Lung Cancer Harboring RET Translocations

STUDY 2016-034
Phase I
A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

STUDY 2016-134
Phase II
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

STUDY 2016-092
Phase I
An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Phase I Advanced Solid Tumors

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2015-086
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1(PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2015-131
Phase II
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2013-120
Phase I
A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents

RECURRENT
ALK
STUDY 2009-139  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Other Genetic Marker  
STUDY 2009-139  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

SCLC EXTENSIVE  
STUDY 2016-099  
Phase I  
An Intensive QT/QTc Study to Investigate the Effects of Rovapituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects with Small Cell Lung Cancer

MESOTHELIOMA  
STUDY 2015-010  
Phase II  
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma

SARCOMA  
STUDY 2009-139  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

OTHER  
STUDY 2009-139  
Phase I  
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY EAY131  
Phase II  
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-189  
Phase I  
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

STUDY S1403  
Phase II/III  
A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)(BI 1200.124)

STUDY 2016-116  
Phase II  
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2015-156  
Phase I  
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced
Solid Tumors

**STUDY 2016-025**
Phase I/II
A Multi-Center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy

**STUDY 2015-086**
Phase I
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death-1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies

---

To refer a patient or for more information on open clinical trials at the Karmanos Cancer Institute, call **1-800-KARMANOS** (1-800-527-6266)

To schedule an appointment, please call between 7:30 AM – 5:30 PM, Monday – Friday

©2016 Karmanos Cancer Institute

This email was sent to alphacat68@gmail.com. To ensure that you continue receiving our emails, please add us to your address book or safe list.

manage your preferences | opt out using TrueRemove®.

Got this as a forward? Sign up to receive our future emails.